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Background: BMI (body mass index) can be misleading regarding the level of adiposity in a normal-weight individual.
Recently, a bioelectrical impedance analysis (BIA) method was developed that can measure body composition variables.
The main objectives of this study were to use BIA to compare the body composition variables between chronic non-
diabetic schizophrenic patients with normal weight and healthy individuals. The secondary objective was to compare
the nutritional pattern of schizophrenia patients with that of matched healthy subjects, and to identify possible
relationships between the content of different components of their diet and visceral adiposity.
Methods: The subjects were 52 normal-weight patients (33 males and 19 females) diagnosed with schizophrenia
based on the DSM-IV and 45 (23 males and 22 females) BMI- matched controls. The patients had been receiving
atypical or typical antipsychotic agents for at least one year before enrollment into the study but continuously for
3 months preceding the study and were psychiatrically stable. Body fat (kg), percent (%) body fat, fat-free mass, VAT
(visceral adipose tissue) and SAT (subcutaneous adipose tissue) were measured using the bioelectrical impedance
analysis (BIA) method. Daily food rations (DFR) were quantitatively evaluated by a 24-h dietary recall method covering
3 days preceding the examination.
Results: In normal-weight patients schizophrenia was significantly linked with higher VAT, VAT/SAT ratio and lower
fat- free mass. Men had over 5 times and women over 2 times as much VAT as BMI matched groups. In women with
schizophrenia and in their controls, the amount of magnesium, niacin and vitamin B6 in their diet inversely correlated
with VAT, while in men lower zinc and vitamin C intake was related to higher visceral adiposity.
Conclusions: Our study has shown that normal-weight patients with chronic schizophrenia have higher levels of
visceral fat (VAT) than controls but similar volume of subcutaneous adipose tissue (SAT). Although no clear conclusion
can be made regarding cause-and-effect relationships between the dietary content of food served to our patients and
visceral obesity, we suggest that schizophrenia diet should be further investigated as a possible factor related to this
type of obesity.
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In 1981, Ruderman described the phenotype of “meta-
bolically obese but normal weight” (MONW) individuals
[1]. These lean individuals mark a departure from com-
mon human patterns, in which a metabolic disease is a
consequence of weight gain. MONW subjects display an
altered insulin sensitivity and a higher abdominal and* Correspondence: beatajan0@op.pl
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article, unless otherwise stated.visceral adiposity. Visceral obesity puts a strain on the
entire circulatory system leading to raised blood choles-
terol and triglyceride levels, lower HDL cholesterol
levels, increased likelihood of overall cardiovascular risk
and associated morbidity and mortality [2,3]. As subjects
with visceral obesity might have normal weight, they
may escape detection and may not benefit from ad-
equate early prevention of metabolic syndrome [4]. Most
schizophrenic patients under neuroleptic treatment gain
weight [5,6]. However, some of them maintain a normal
weight, despite long-term pharmacotherapy and eatingentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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Konarzewska et al. BMC Psychiatry 2014, 14:35 Page 2 of 9
http://www.biomedcentral.com/1471-244X/14/35habits similar to those of overweight patients [4]. It is
known that patients with schizophrenia make poor diet-
ary choices and they have a tendency to [7,8] have in-
creased caloric intake, including a higher total dietary fat
consumption than healthy individuals [8]. Usually, they
are also physically inactive; they spend most of the time
passively [9-11]. They have higher levels of cortisol and
insulin prior to neuroleptic treatment, which make them
particularly susceptible to the accumulation of visceral
fat [12]. Previous studies which have found an increased
visceral adiposity in schizophrenic patients analyzed pa-
tients with both normal and abnormal body weight, and
not always a test and control group were adjusted for BMI
[13,14]. None of them focused entirely on normal-weight
patients. These individuals may as well present an un-
favorable metabolic body composition and significant vis-
ceral obesity even though they had normal body weight.
BMI is a commonly used measure in people with
schizophrenia, but there are no data indicating its sensi-
tivity and specificity as an indicator of visceral adiposity
among this clinical group. Both BMI and waist circum-
ference are more strongly correlated with subcutaneous
(SAT) than with visceral fat (VAT). Although BMI corre-
lates highly with fat mass, depending on level of muscu-
larity, it can be misleading regarding the level of
adiposity of an normal weight individual [15]. Recently,
a bioelectrical impedance analysis (BIA) method was de-
veloped that can measure body composition variables
[16]. BIA is based on the principle that there is less re-
sistance to an alternating current passing through tissues
that contain fluids and electrolytes than through those
containing relatively high amounts of lipids [17]. Its re-
sults correlate well with the results of dual energy X-ray
absorptiometry (DXA) [18].
The main objectives of this study were to use BIA to
compare the body composition variables between chronic
non-diabetic schizophrenic patients with normal weight
(BMI <25 kg/m2) and healthy individuals. We sought to
define the magnitude of visceral obesity in both groups in
terms of elevated VAT volumes. The second objective was
to compare the schizophrenia patients, who in previous
studies appeared to have a poor diet [7,8] with matched
healthy subjects and to identify possible relationships be-
tween the content of different components of their diet
and visceral adiposity. We hypothesized that schizophre-
nia patients food intake which contains inadequate
amounts of fibre, vitamins and minerals might be linked
with the tendency to accumulate visceral fat.
Methods
Participants
This study was conducted between October 2012 and
March 2013. The subjects were 52 normal-weight (BMI <
25 kg/m2) patients (33 males and 19 females) treated inPsychiatric Hospital, Social Care Unit for Mentally Dis-
abled Patients in Choroszcz and Day Care Center in
Bialystok (Poland). They were diagnosed with schizophre-
nia disorder based on the DSM-IV diagnostic criteria. The
age of schizophrenia onset and the length of the disease
for males and females were as follows (males 28.9 years;
12.2 years) and (females 25.4 years; 13.2 years). As a refer-
ence group, 45 matched healthy subjects (23 males and 22
females) were also included. Patients had been receiving
atypical or typical antipsychotic agents for at least one
year before enrollment into the study but continuously for
3 months preceding the study and were psychiatrically
stable. Medication doses in men and women at the time
of the study expressed as chlorpromazine equivalents were
as follows (males 891.1 mg; females 722.1 mg).
Sixteen of them have been receiving 1 neuroleptic, 17
patients- 2 or 3 neuroleptics, concomitantly. The most
commonly used were: olanzapine, risperidone, haloperi-
dol and clozapine. Exclusion criteria included serious
and unstable medical conditions, cognitive disorders,
substance dependence within the previous 3 months,
known medical conditions which might affect changes in
metabolic parameters, known history of diabetes (pa-
tients with glucose levels ≥ 126 mg/dL were excluded
from the study) or lipid disorder, use of anti-diabetic or
lipid-lowering therapy and special diets to lower glucose
or lipids levels. The study was approved by the Bio-
ethical Committee of the Medical University of Bialys-
tok, Poland. Informed written consent was obtained
from all the subjects after explanation of the nature, pur-
pose, and potential risks of the study.
Procedures
After providing written informed consent, each subject
underwent a physical examination and a psychiatric
diagnostic evaluation. Anthropometric measures, includ-
ing weight, height, umbilicus waist circumference and
hip circumference, were obtained. Body composition
was measured by means of a bioelectrical impedance
analysis (BIA) technique using a Maltron body fat
analyzer (Maltron BioScan 920) with an operating fre-
quency of 50 kHz at 800 μA [19]. All measurements
were taken around the same time of the day after pa-
tients have sat quietly and rested for at least 15 min.
The participants lay supine on a non-conducting surface
with their arms abducted from the trunk and legs
slightly separated for 5 minutes. Four electrodes and ca-
bles were attached to the right hand and ankle, as shown
in the user’s manual. When the measurements stabilized,
the analyzer displayed bioelectrical impedance directly
and immediately through the calculation of the software.
According to the strong relationships among measured
impedance, fat-free mass (FFM), and total body water,
many prediction equations were developed to estimate
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data, the percentage of body fat and FFM, could also be
directly displayed after BIA measurement. Previous stud-
ies demonstrated excellent test-retest reliability for BIA-
obtained measurements, with correlation coefficients
ranging from .96 to .99 for resistance measurements
[21]. Hydrostatic weighing and BIA-predicted correl-
ation coefficients range from .71 to .93, with standard er-
rors of estimate ranging from 2.7% to 4.7% body fat [22].
The measurement procedure required that the subject
should stand barefoot on the analyzer and hold a pair of
handgrips, one in each hand. The device uses a multiple-
frequency (5 kHz, 50 kHz, 250 kHz, and 500 kHz) BIA
technology and has 8 tactile electrodes: 2 are in contact
with the palm and thumb of each hand, and 2 are in con-
tact with the anterior and posterior aspect of the sole of
each foot. To calculate the body fat, percent (%) body fat,
fat- free mass, VAT (visceral adipose tissue), SAT (sub-
cutaneous adipose tissue), muscle mass, and body water
for the entire body, the MC-190 uses a proprietary equa-
tion developed by the manufacturer.
Daily food rations (DFR) were quantitatively evaluated
by a 24-h dietary recall method covering 3 days preced-
ing the examination. The portion sizes of dishes and
food products were estimated based on the “Photo
Album of Food Products and Dishes” [23]. The energy
and nutritional values of the diets were calculated with
Diet 5 computer software designed by the Institute of
Food and Feeding (IFF) in Warsaw. The findings were
compared with the recommended dietary allowance
(RDA) or Adequate Intake (AI) proposed by the IFF for
healthy adults who report low physical activity [24]. The
mean demand for energy and basic nutrients was deter-
mined individually referring to due body mass. The in-
take of protein at 0.9 g/kg of due body mass and fat
covering 30% of the anticipated energy demand was re-
ferred to as the norm. The carbohydrate demand was
calculated from the difference between daily energy de-
mand and the energy derived from protein and fats. The
demand for saturated and mono- and polyunsaturated
fatty acids was determined at 10%, 12% and 8% of energy
demand, respectively. The daily norm for dietary fibre
was 30 g, whereas for dietary cholesterol it was not more
than 300 mg.Table 1 Study groups characteristics
Male
Schizophrenia N = 33 Controls N = 23 P
Age (years) 46 (31, 57) 42 (27, 53)
Body weight (kg) 70 (68, 75) 74.4 (66, 77)
Height (cm) 175 (172, 178) 179 (170, 186)
BMI 23.3 (22.3, 24) 23.5 (22.3, 24.2)
WHR 0.9 (0.9, 0.9) 0.9 (0.9, 0.9)Statystical analysis
Due to the small size of the groups we used nonpara-
metric tests. To compare the main demographic and
clinical characteristics between patients and controls,
Mann–Whitney U test was performed. Descriptive sta-
tistics were calculated as median with the interquartile
range: median (IQR). Multiple linear regression analysis
was employed to analyze the continuous variables of
body composition (independent variables were: gender,
the occurrence of schizophrenia, age and BMI). Healthy
women were used as the reference category The rela-
tionship between selected variables were evaluated using
the Spearman correlation coefficient. A value of p < 0.05
was considered significant. The data were analyzed using
the package Statistica 10.0 StatSoft.
Results
The basic characteristics and body composition of par-
ticipants are presented in Tables 1 and 2.
There were no statistical between-group differences in
age, body mass, height and BMI. In females, WHR (waist
hip ratio) was significantly higher in patients with schizo-
phrenia than in healthy individuals. RMR (resting meta-
bolic rate) and fat free mass (kg), were in all groups
positively correlated (males with schizophrenia r = 073,
p = <0.001, n = 33, controls r = 0.83, p = p = <0.001, n = 23;
women schizophrenia 0.53, p = 0.02, n = 19, controls r =
0.56, p = 0.007, n = 22). Furthermore, RMR and fat free
mass were significantly lower in patients with schizophre-
nia than in healthy individuals (Table 1). Both groups of
men and women did not differ with regard to the SAT. In
both males and females VAT and VAT/SAT ratio were sig-
nificantly higher in patients with schizophrenia than in
healthy individuals (Table 2). Within schizophrenia groups
the only demographic variable that correlated positively
with visceral obesity, namely with VAT/SAT ratio was the
length of the disease, however, this type of relationship
was observed exclusively among males (Spearman correl-
ation r = 0.51, p = 0.01, n = 23). There were no significant
differences between men and women with respect to the
onset of schizophrenia and the duration of the disease.
Multiple regression analysis for the detailed body com-
position characteristics. Healthy women were used as
the reference category.Female
value Schizophrenia N = 19 Controls N = 22 P value
0.368 41 (30, 47) 39.5 (30, 47) 0.990
0.133 59 (54, 68) 58.5 (54.7, 64.2) 0.783
0.236 164 (161, 170) 167.5 (163, 170) 0.511
0.516 21.8 (20.8, 24.1) 20.9 (20.1, 22.1) 0.302
0.434 0.89 (0.85, 0.92) 0.84 (0.79, 0.86) 0.009
Table 2 Body composition measurements of patients with schizophrenia and controls
Males Females
Schizophrenia N = 33 Controls N = 23 P value Schizophrenia N = 19 Controls N = 21 P value
Fat free mass (kg) 57.2 (54, 59.9) 62.5 (54.8, 66) 0.010 43.4 (41.8, 45.6) 44.7 (42.6, 46.1) 0.229
Fat free mass (%) 81.2 (78.8, 85) 83.9 (78.5, 86.5) 0.286 72.8 (70.1, 77.4) 74.5 (70.1, 77.3) 0.804
Body fat (kg) 13.3 (10, 15.7) 11.5 (10.3, 16.3) 0.653 16 (12.2, 19.3) 15.3 (12.5, 18.3) 0.824
% Body fat 18.8 (14.4, 21.2) 16.1 (13.5, 19.7) 0.194 27.2 (22.6, 29.9) 25.5 (22.7, 29.9) 0.695
RMR (kcal) 1798 (1585, 1885) 1820 (1704, 2120) 0.050 1427 (1390, 1517) 1479 (1435, 1520) 0.472
VAT (cm2) 351.9 (262, 586.8) 73 (52, 201) 0.000 124 (56, 281) 55.5 (39, 84) 0.006
SAT (cm2) 88 (80, 112) 108 (78, 139) 0.286 82 (65, 92) 80.5 (73, 101) 0.565
VAT/SAT ratio 3.5 (2.5, 5) 0.7 (0.5, 1.9) 0.000 1.4 (0.6, 3.5) 0.7 (0.5, 1) 0.005
Table 3 Multiple regression analysis for the detailed body
composition characteristic
Beta coefficient P value R2
Fat free mass (kg)
Gender 14.101 P < 0.001
Schizophrenia −2.990 0.001 0.757
Age −0.134 P < 0.001
BMI 0.925 P = 0.001
Fat free mass (%)
Gender 11.546 P < 0.001
Schizophrenia −0.496 0.376 0.801
Age −0.105 P < 0.001
BMI −2.123 P < 0.001
Body fat (kg)
Gender −6.109 P < 0.001
Schizophrenia −0.063 0.899 0.697
Age 0.006 0.004
BMI 2.023 P < 0.001
Body fat (%)
Gender −11.642 P < 0.001
Schizoprenia 0.646 0.268 0.788
Age 0.106 P < 0.001
BMI 2.051 P < 0.001
VAT
Gender 169.451 <0.001





Schizophrenia 2.098 P < 0.001 0.280
Age 0.019 0.265
BMI −0.171 0.207
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associations between the diagnosis of schizophrenia and
body composition in normal-weight patients with
schizophrenia are presented in Table 3. Schizophrenia
was significantly associated with lower fat- free mass
(kg), higher VAT and VAT/SAT ratio. There was a close
relationship between the male gender and higher VAT
and VAT/SAT ratio. Subjects’ age and BMI were posi-
tively related to higher values of fat mass (kg) but in-
versely with % fat free mass.
The analysis of the food intake showed that daily food
rations of men with schizophrenia compared to those of
healthy subjects provided less kcal/day. Also glucose,
proteins and fibre consumption was lower in this group.
On the other hand, the mean intake of saturated fats in
the diets of women with schizophrenia was higher com-
pared to controls (Tables 4 and 5). Daily food rations of
men with schizophrenia provided lower amounts of vita-
mins (B2, C) and minerals (zinc, magnesium, iron, cop-
per, calcium). Additionally, the intake of vitamin D3, C,
folic acid, calcium, magnesium in men, and in women
with schizophrenia also iron, did not cover daily require-
ments for these components (RDA) (Tables 6 and 7).
In female group, the presence of high amount of satu-
rated fatty acids in their diet was positively related to fat
mass (kg) (women with schizophrenia, r = 0.73, p =
0.0007, n = 17). In women with schizophrenia and in
their controls, the amount of magnesium, niacin, vitamin
B6, and in men diagnosed with schizophrenia, lower zinc
and vitamin C, was inversely correlated with the VAT or
VAT/SAT ratio (Table 8).
Discussion
This study was the first to compare body composition of
normal-weight, non-diabetic, chronic schizophrenia pa-
tients with that of healthy controls. The main findings of
this study were that both normal-weight men and
women with schizophrenia had visceral fat content
significantly higher compared to that of the control
groups, while there was no difference with respect to the
Table 4 Energy and nutritional value of daily food rations of the male study participants
Schizophrenia (N = 27) Controls (N = 22)
Median (IQR) % realization of
the norm and
recommendations




Energy (kcal) 1719.9 (1464.8, 2313.3) 63.7 2114.4 (1855.5, 2722) 78.3 0.021
Water (ml) 1537 (1234.4, 1820.6) 41.5 1700.4 (1413.8, 2462.4) 45.9 0.07
Proteins (total) (g) 62.6 (52.8, 86) 77.2 102.2 (68.9, 108.5) 126.1 0.004
Proteins (animal) (g) 44.1 (32.9, 52.2) 110.2 70.2 (40.9, 85.2) 175.5 0.015
Fat (g) 67.2 (48, 91.3) 74.6 73.4 (53.7, 103.2) 81.5 0.594
Carbohydrates total (g) 235.2 (152.6, 274.4) 60.1 320.3 (219.3, 374.7) 81.9 0.011
Saturated fatty acids (g) 32.2 (17.8, 39.7) 107.3 27.9 (22.1, 39.6) 93.0 0.786
Monounsaturated fatty acids (g) 27.4 (19.5, 39.6) 76.1 27.5 (21, 150.3) 76.3 0.771
Polyunsaturated fatty acids (g) 6.8 (4.1, 9.8) 28.3 7.9 (5.7, 12.6) 32.9 0.140
Cholesterol (mg) 240.7 (187.3, 417) 80.2 306.2 (233.1, 484.6) 102.0 0.540
Fibre (mg) 14.8 (49.3%) (11.4, 18.1) 49.3 18.3 (14.5, 25.7) 61.0 0.041
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in both males and females with schizophrenia visceral
adiposity was higher compared to controls, mainly the
male gender was associated with higher values of VAT,
VAT/SAT ratio. The mechanism for increased visceral
fat in schizophrenic patients has not been completely
elucidated. Patients with schizophrenia are at risk of de-
veloping obesity due to poor dietary habits, lower resting
energy expenditure, lack of exercise or limited activity
due to negative symptoms of schizophrenia. Previous
studies have suggested an increased propensity for stor-
ing excess fat as visceral adiposity in schizophrenic pa-
tients [12,14]. Ryan at al. (2004) have shown that even
first episode, drug-naïve patients with schizophrenia had
over three times as much visceral fat as BMI-matched con-
trols. In their study, drug-naïve patients with schizophreniaTable 5 Energy and nutritional value of daily food rations of
Schizophrenia (N = 17)
Median (IQR) % realizati
the norm
recommen
Energy (kcal) 1621.3 (1460.1, 1915.3) 77.2
Water (ml) 1561.4 (1376.4, 1711.3) 57.8
Proteins (total) (g) 64.2 (53.8, 69.1) 101.9
Proteins (animal) (g) 37.8 (29.7, 48.5) 118.1
Fat (g) 44.3 (40.1, 58.5) 63.3
Carbohydrates total (g) 253.3 (183, 306.5) 83.3
Saturated fatty acids (g) 20 (16.5, 27.9) 86.9
Monounsaturated fatty acids (g) 17.4 (16.3, 29.2) 62.1
Polyunsaturated fatty acids (g) 5.2 (4.2, 5.6) 27.4
Cholesterol (mg) 190.7 (157.6, 252.4) 63.6
Fibre (mg) 16.2 (13.3, 209) 54were hypercortisolemic, consumed less fibre though more
saturated fat, had higher WHRs, and had just over 3 times
as much VAT as the BMI matched group of control sub-
jects [12]. According to the authors, the most likely patho-
physiological mechanism underlying this increase in
visceral obesity in schizophrenia was hypercortisolemia.
High levels of cortisol primarily increase LPL activity, and
do so to a greater extent in VAT fat cells, thereby leading
to a greater deposition of visceral fat [25]. Ryan et al.
(2004) also analysed the impact of risperidone and olanza-
pine treatment on VAT and concluded that they do not
appear to play a part in the generation of excessive levels
of visceral fat in their group of never-treated patients with
schizophrenia [12].
Our sample, in contrast to the previous study, con-
sisted of patients with normal weight (BMI < 25 kg/m2)the female participants








1378.8 (1131, 1636) 65.6 0.057
1804.5 (1386.3, 2230.8) 66.8 0.156
59.5 (54.3, 93.1) 94.4 0.532
45.9 (35.9, 67.8) 143.4 0.065
37.8 (25.9, 57.5) 54 0.097
182.8 (144.9, 221.2) 60.1 0.070
14.4 (10.4, 20.1) 62.6 0.034
14.4 (9.7, 23) 51.4 0.110
4.4 (3.7, 5.5) 23.1 0.353
194.8 (127.8, 266.5) 64.9 0.915
14.9 (12.1, 17.4) 49.6 0.511
Table 6 Supply of vitamins and minerals in daily food rations (male participants)
Schizophrenia (N = 27) Controls (N = 22)
Median (IQR) % realization of
the norm and
recommendations




Ca (mg) 390.4 (247.8, 588.3) 39.0 (AI) 580.6 (353.4, 940.3) 58.1 (AI) 0.029
P (mg) 896.9 (797, 1172.4) 128.1 (RDA) 1411.2 (1019.2, 1868.7) 201.6 (RDA) 0.002
Mg (mg) 227.1 (165.7, 293) 54.1 (RDA) 314.4 (221.5, 410.4) 74.8 (RDA) 0.003
Fe (mg) 8.5 (7.3, 11.4) 85.0 (RDA) 12.4 (8.6, 14.1) 124.0 (RDA) 0.025
Zn (mg) 8.4 (7.7, 11 8) 76.4 (RDA) 11.2 (8.8, 15.7) 101.8 (RDA) 0.031
Cu (mg) 0.9 (0.7, 1.1) 100 (RDA) 1.3 (0.9, 1 5) 144.4 (RDA) 0.003
B1 (mg) 1.3 (0.9, 1.8) 100 (RDA) 1.5 (1.1, 2.8) 115.3 (RDA) 0.101
B2 (mg) 1.2 (0.9, 1.6) 92.3 (RDA) 1.7 (1.3, 2.5) 130.7 (RDA) 0.007
Niacyn (mg) 13.7 (11, 17.8) 85.6 (RDA) 17.7 (11, 30.3) 110.6 (RDA) 0.145
B6 (mg) 1.7 (1.3, 2.1) 130.7 (RDA) 2.1 (1.5, 2.6) 161.5 (RDA) 0.115
C (mg) 29.4 (21.8, 58.7) 32.6 (RDA) 67.6 (31.3, 105.4) 75.1 (RDA) 0.024
Folic acid (μg) 187 (139.8, 235.8) 46.7 (RDA) 242.2 (176.4, 288.2) 60.5 (RDA) 0.075
D (μg) 1.9 (1.3, 3.3) 38 (AI) 2.3 (1.6, 3.6) 46.0 (AI) 0.282
RDA-Recommended Dietary Allowances; AI-Adequate Intake.
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were more prone to higher VAT levels although the
mean intake of absorbable carbohydrates and saturated
fats in the diets of women with schizophrenia was
higher, as compared to controls. Men had over 5 times,
while women over 2 times as much VAT as the BMI-
matched groups did. Both BMI and age of the patients
did not affect the contents of the VAT. Higher VAT and
lower fat free mass (kg) was directly related to schizo-
phrenia, while body fat mass positively correlated withTable 7 Supply of vitamins and minerals in daily food rations
Schizophrenia (N = 17)
Median (IQR) % realization of
the norm and
recommendations
Ca (mg) 474.1 (208.6, 616.3) 47.4 (AI)
P (mg) 1068.6 (806.5, 1262.1) 152.6 (RDA)
Mg (mg) 261.7 (175.2, 360.3) 81.8 (RDA)
Fe (mg) 8.4 (7.4, 10) 46.6 (RDA)
Zn (mg) 8.6 (7.3, 9.9) 107.5 (RDA)
Cu (mg) 0.8 (0.6, 1.1) 88.8 (RDA)
B1 (mg) 1.0 (0.8, 1.2) 90.9 (RDA)
B2 (mg) 1.2 (0.8, 1.5) 109 (RDA)
Niacyn (mg) 10.3 (6.4,16.7) 73.6 (RDA)
B6 (mg) 1.3 (1, 1.5) 100 (RDA)
C (mg) 31.9 (17.5, 40.7) 42.5 (RDA)
Folic acid (μg) 164.7 (139.8, 204.9) 41.2 (RDA)
D (μg) 1.3 (0.9, 2.1) 26 (AI)
RDA-Recommended Dietary Allowances; AI-Adequate Intake.the subjects’ age and BMI. Our results turned to be only
partly consistent with other studies investigating body
mass composition in schizophrenia patients chronically
exposed to neuroleptic treatment. In a study by Sugawara
et al. (2012), schizophrenia was significantly linked with
more body fat, higher % body fat and lower fat- free mass
[26]. Contrary to men, in women schizophrenia had a sig-
nificant association with lower % body fat, higher fat- free
mass, higher muscle mass. In turn, Nilsson et al. (2006)
found that patients with schizophrenia had higher % body(female participants)
Controls (N = 20)




434.6 (280.2, 612.1) 43.5 (AI) 0.988
1088 (837.5, 1248.7) 108.8 (RDA) 0.796
222.8 (177.5, 306.1) 69.6 (RDA) 0.939
7.4 (6.1, 10.6) 41.1 (RDA) 0.512
8.2 (5.5, 10.4) 102.5 (RDA) 0.552
0.9 (0.7, 1.1) 100 (RDA) 0.784
1.1 (0.8, 1.3) 90.9 (RDA) 0.879
1.3 (1.2, 1.6) 108.3 (RDA) 0.377
12.7 (8.3, 24.3) 90.7 (RDA) 0.124
1.5 (1.4, 1.7) 115.4 (RDA) 0.097
60.7 (32.6, 108.9) 80.9 (RDA) 0.020
186.6 (161, 231.8) 46.6 (RDA) 0.110
1.6 (0.9, 2.1) 32 (AI) 0.927
Table 8 Spearman rank correlations between nutrients and VAT1 or VAT/SAT ratio2
Female Males
Schizophrenia Controls Schizophrenia Controls
R P R P R P R P
Niacin −0.50 0.042 −0.52 0.022 Vit. C −0.47 0.012 −0.51 0.012
Vit. B6 −0.63 0.0061 −0.5 0.022 Zn −0.45 0.022 - -
Mg −0.60 0.011 −0.47 0.041 - - - - -
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Saarni et al. (2009) reported that schizophrenia was sig-
nificantly associated with a higher % body fat and lower
fat- free mass after adjusting for age, gender, and BMI
[13]. Nevertheless, all of these studies showed smaller con-
tent of the fat free mass in patients with schizophrenia.
The differences between our results and data from other
studies may be due to the fact that the previous studies in-
cluded patients who were overweight, samples were not
always BMI- matched and the body fat content was not
differentiated in terms of its location: into visceral and
subcutaneous fat depot. Most previous studies also used
different methods than BIA, and analyzed a mixed subject
pool of both genders or only male subjects.
In our chronically treated patients, the only demo-
graphic variable that correlated positively with visceral
depot besides schizophrenia was the length of the dis-
ease. However, this type of relationship was observed ex-
clusively among males. This may be partially explained
by the use of antipsychotic medication and unhealthy
lifestyle habits. Antipsychotic medications, especially
atypical, have been associated with significant weight
gain and visceral obesity [28]. In Zhang et al. (2004)
study an antipsychotic drug treatment rapidly induces
abdominal fat deposition and hyperlipidaemia. There-
fore, it may be possible for older subjects with a longer
duration of the disease to have higher VAT, since nor-
mally they have been on antipsychotic medication for a
longer period of time.
Another factor which was related with the amount of
VAT in our study was the components of the patients’
diet. In women with schizophrenia, the presence of high
amount of saturated fatty acids in their diet was posi-
tively related to fat mass. The analysis of the food intake
showed that daily food rations of men diagnosed with
schizophrenia provided less calories, proteins, glucose
and fibre compared to controls, whereas women, while
providing a similar amount of calories, tend to eat more
saturated fatty acids. The results of our study point to
the fact that patients with schizophrenia with normal
weight do not have a tendency to consume excessive
amounts of calories, quite the contrary. Thus, the accu-
mulation of visceral fat in this group may be due to im-
proper composition of the food rather than due to
excessive daily calorie intake. Daily food rations of mendiagnosed with schizophrenia provided also smaller
amounts of vitamins (B2, C) and minerals (zinc, magne-
sium, iron, copper, calcium). In women with schizophre-
nia and in their controls, the amount of magnesium,
niacin and vitamin B6 in their diet was inversely corre-
lated with the VAT, while in men lower zinc and vitamin
C intake was related to higher visceral adiposity. Numer-
ous studies have provided evidence that the above-
mentioned components of the diet are associated with
energy metabolism. Magnesium has been linked with a
number of chronic diseases, including diabetes, hyper-
tension and lipid abnormalities [29]. Magnesium defi-
ciency [30] was described a common factor associated
with insulin resistance [31], which impairs energy me-
tabolism efficiency and reduces the capacity for physical
work, exerts negative effects on blood glucose homeosta-
sis, and is independently associated with depressive
symptoms [32-35]. In addition, magnesium intake in two
studies was inversely associated with the metabolic syn-
drome and risk of type 2 DM [36]. In turn, niacin has
been reported to decrease VLDL, LDL and small dense
LDL particles and increase HDL levels resulting in an
overall beneficial lipoprotein profile. Niacin in Kamanna
and Kashyap (2000) study reduced plasma free fatty acid
levels by inhibiting adipose tissue lipolysis, thereby de-
creasing available substrate for hepatic VLDL synthesis
[37]. Niacin, alone or in combination with statins, has
demonstrated effectiveness in reducing the progression
of atherosclerosis in hypertriglyceridemic individuals
with coronary disease in old or small studies [37-39].
Vitamin B6, although not directly related with energy
metabolism, is essential for the brain regional synthesis
of 5-HT (serotonin). In turn, serotonin has been impli-
cated in various CNS functions that regulate sleep onset,
blood pressure, mood but also food intake satiety
[40,41]. In turn, zinc ions in Chen et al. study (1988) in-
fluenced adipose tissue metabolism by regulating leptin
secretion and by promoting free fatty acid release and
glucose uptake [42]. Apart from participating in the con-
trol of leptin secretion, zinc also seems to be intimately
involved in glucose- and fat-metabolism in adipocytes,
where zinc per se has a role as an insulinomimetic [43].
There is clear evidence that visceral obesity is associated
with increased oxidative stress and inflammation [44].
Another recent data also suggest that dietary antioxidants,
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to develop metabolic syndrome features such as adiposity
or impairments in systolic blood pressure, serum glucose
and free fatty acids, and some inflammatory biomarkers in
healthy subjects [45].
Conclusions
It is difficult to draw conclusions from this study as its
limitations include a relatively small sample size and the
fact that daily food rations were evaluated by a method
covering 3 days preceding the examination. Despite
these shortcomings, our study has shown that normal
weight patients with chronic schizophrenia have higher
levels of visceral fat than controls but a similar volume
of SAT. Although in both males and females with
schizophrenia the visceral adiposity was higher com-
pared to controls, mainly the male gender was associated
with higher values of VAT and the VAT/SAT ratio.
Schizophrenia patients have poor nutritional patterns.
Although no clear conclusion can be drawn regarding
cause-and-effect relationships between the dietary con-
tent of food served to our patients and visceral obesity
we suggest that schizophrenic diet should be further in-
vestigated as a possible factor related to this type of
obesity.
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